Type 2 Diabetes Mellitus
A common condition where the body becomes resistant to its own insulin, causing blood sugar levels to rise dangerously high over time.
Emergency Management: Hyperosmolar Hyperglycemic State (HHS). Occurs in older T2DM patients, often triggered by severe infection. Massive osmotic diuresis leads to profound dehydration (fluid deficit can be up to 9-10 Liters). Requires immediate ICU admission for aggressive IV Normal Saline hydration, followed by IV insulin therapy. Mortality is higher than in DKA.
Type 2 Diabetes Mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from a complex interplay of progressive peripheral insulin resistance and a relative impairment in pancreatic beta-cell insulin secretion.
Detailed Overview
T2DM is the most common form of diabetes, comprising over 90% of cases globally. It is heavily driven by environmental and lifestyle factors, particularly central obesity, physical inactivity, and hypercaloric diets. Initially, the pancreas compensates for peripheral insulin resistance by hypersecreting insulin. Over time, beta-cell exhaustion and apoptosis occur, leading to relative insulin deficiency. Unlike Type 1, T2DM patients rarely develop spontaneous ketoacidosis. The primary burden of T2DM is the insidious development of devastating macrovascular (myocardial infarction, stroke) and microvascular (retinopathy, nephropathy, neuropathy) complications over decades.
Epidemiology & Demographics
A global epidemic. Affects over 450 million people worldwide (approx. 10.5% of the adult US population). Historically an adult-onset disease (>40 years), incidence in youth and adolescents is rising alarmingly parallel to pediatric obesity rates. Higher prevalence in Native American, African American, Hispanic, and South Asian populations.
Etiological Mechanism
A polygenic disorder strongly modified by lifestyle. Obesity (specifically visceral adiposity) causes chronic low-grade systemic inflammation and alters adipokine secretion, directly impairing insulin receptor signaling in muscle and liver tissues.
Primary Causes
Insulin resistance in peripheral tissues (skeletal muscle, liver, adipose) combined with progressive beta-cell dysfunction. Excess visceral fat releases free fatty acids and inflammatory cytokines (TNF-alpha, IL-6) which interfere with the insulin signaling cascade (IRS-1).
Pathology involves the 'Ominous Octet', including: 1) Decreased peripheral glucose uptake (muscle resistance). 2) Increased hepatic glucose production (liver resistance to insulin-mediated suppression of gluconeogenesis). 3) Decreased incretin effect (GLP-1/GIP deficiency) reducing postprandial insulin release. 4) Increased lipolysis in adipocytes releasing free fatty acids. 5) Increased glucagon secretion from pancreatic alpha cells. 6) Increased renal glucose reabsorption via SGLT2 up-regulation. 7) Brain neurotransmitter dysfunction altering appetite. 8) Progressive pancreatic beta-cell failure and apoptosis due to glucotoxicity and lipotoxicity. This multiorgan dysfunction results in sustained fasting and postprandial hyperglycemia.
Diagnostic Criteria & Guidelines
Same as Type 1: Fasting Plasma Glucose (FPG) >= 126 mg/dL, OR 2-hour Plasma Glucose >= 200 mg/dL during a 75g OGTT, OR Hemoglobin A1c (HbA1c) >= 6.5%, OR random plasma glucose >= 200 mg/dL with classic symptoms. Diagnosis must be confirmed with a repeat test on a separate day unless classic symptoms with random glucose >200 mg/dL are present.
Lifestyle modification (weight loss, Mediterranean diet, exercise) PLUS Metformin. Metformin (start 500 mg PO daily, titrate to 1000 mg PO BID) acts primarily by decreasing hepatic gluconeogenesis and does not cause hypoglycemia or weight gain.
Second-Line & Adjunctive Therapy
If HbA1c is not at target, or if patient has ASCVD, Heart Failure, or Chronic Kidney Disease: Add a GLP-1 Receptor Agonist (e.g., Semaglutide 0.25-2.0 mg SC weekly - excellent for weight loss and CV benefit) OR an SGLT2 Inhibitor (e.g., Empagliflozin 10-25 mg PO daily - excellent for heart failure and renal protection). Other options include DPP-4 inhibitors or Sulfonylureas.
Surgical & Procedural Management
Metabolic/Bariatric Surgery (e.g., Roux-en-Y gastric bypass or sleeve gastrectomy) is highly recommended for patients with BMI >= 35 kg/m2 and uncontrolled T2DM. It can induce complete disease remission in up to 60-80% of patients within days of surgery, even prior to significant weight loss.
Patient Counseling & Advice
Daily comprehensive foot exams by the patient are mandatory to check for painless cuts or blisters. Stress that T2DM is a progressive disease; needing to start insulin in the future is not a 'failure' of the patient, but a natural progression of beta-cell burnout. Strict blood pressure and cholesterol control are just as important as blood sugar control to prevent heart attacks.
Follow-Up & Monitoring Schedule
HbA1c every 3-6 months. Annual screening for microvascular complications: dilated eye exam (retinopathy), urine albumin-to-creatinine ratio (nephropathy), and comprehensive foot exam with 10g monofilament (neuropathy). Routine lipid panel and blood pressure monitoring.
Preventive Strategies
Intensive lifestyle intervention (diet and exercise targeting 7% weight loss) in prediabetic patients reduces the progression to T2DM by 58%. Metformin can be used for prevention in high-risk prediabetics (BMI > 35, history of GDM).
Highly dependent on glycemic and cardiovascular risk factor control. Poorly controlled T2DM reduces life expectancy by up to 10 years, primarily due to myocardial infarction and stroke. Remission is possible early in the disease with profound weight loss.